

Disclosure of ceasing to have substantial holding

Section 279, Financial Markets Conduct Act 2013

To NZX Limited

and

To AFT Pharmaceuticals Limited ("**AFT**")

Date this disclosure made: **25 May 2017**

Date last disclosure made: 23 June 2016

Date on which substantial holding ceased: **25 May 2017**

Substantial product holder(s) giving disclosure

Full name(s): AFT Pharmaceuticals Limited

Summary of previous substantial holding

Class of quoted voting products: Fully paid ordinary shares in AFT (ISIN: NZAFTE0001S4) ("**Shares**")

Summary for AFT Pharmaceuticals Limited

For **last** disclosure,—

- (a) total number held in class: 70,046,535
- (b) total in class: 96,834,838
- (c) total percentage held in class: 72.336%

For current holding **after** ceasing to have substantial holding,—

- (a) total number held in class: Nil
- (b) total in class: 96,834,838
- (c) total percentage held in class: Nil

Details of transactions and events giving rise to ceasing of substantial holding

Details of the transactions or other events requiring disclosure:

Pursuant to the Escrow Deeds (as defined in and attached to AFT's previous event disclosure notice dated 23 June 2016 (the "**Previous SPH Notice**")) AFT had the qualified power to control the disposal of 70,046,535 Shares (the "**Escrowed Shares**") held by the various persons named in the schedule to the Previous SPH Notice.

Pursuant to the Escrow Deeds, the Escrowed Shares are released from the escrow restrictions contained in the Escrow Deeds on the first business day after the date on which AFT releases to NZX Limited its preliminary results for the financial year ending 31 March 2017. AFT released to NZX Limited its preliminary results for the financial year ended 31 March 2017 on 24 May 2017.

As a result of the Escrowed Shares no longer being subject to the escrow restrictions contained in the Escrow Deeds, AFT no longer has a relevant interest in any Shares.

Accordingly the previous qualification to the relevant interests of each of the persons named in the schedule to the Previous SPH Notice no longer applies.

Additional information

Address(es) of substantial product holder(s): Level 1, Nielsen Building, 129 Hurstmere Road, Takapuna, Auckland 0740

Contact details: Malcolm Tubby, Chief Financial Officer

Name of any other person believed to have given, or believed to be required to give, a disclosure under the Financial Markets Conduct Act 2013 in relation to the financial products to which this disclosure relates: N/A

Certification

I, Malcolm Tubby, certify that, to the best of my knowledge and belief, the information contained in this disclosure is correct and that I am duly authorised to make this disclosure by all persons for whom it is made.